Montgomery S A, Rasmussen J G, Tanghøj P
St Mary's Hospital Medical School, London, UK.
Int Clin Psychopharmacol. 1993 Fall;8(3):181-8. doi: 10.1097/00004850-199300830-00008.
A total of 147 patients who had responded in a placebo-controlled study to 6 weeks treatment of an episode of DSM-III-R major depression with either 20 mg or 40 mg citalopram were randomized double-blind to continue on the same dose of citalopram or to receive placebo during a 24-week study of the efficacy of citalopram in the prevention of relapse. The citalopram 20 and 40 mg groups showed a significant advantage compared with placebo both in relapses (p < 0.05) and in the survival analysis of time to relapse (p = 0.01 and p = 0.02, respectively). Both 20 and 40 mg citalopram appeared similarly safe and well tolerated with little difference in side effects from placebo. The results demonstrate that citalopram, at a dose of both 20 and 40 mg is effective and well tolerated in continuation treatment to consolidate response. The relapse rate in patients who had responded to placebo during the 6-week acute treatment study, who were continued double-blind with placebo but not included in the efficacy analysis, was similar to the rate in the formal placebo control group, suggesting that patients who respond to placebo in a short treatment course may nonetheless require long-term active treatment to prevent relapse.
在一项安慰剂对照研究中，共有147例对20毫克或40毫克西酞普兰治疗DSM-III-R重度抑郁症发作6周有反应的患者，被随机双盲分为继续服用相同剂量的西酞普兰或在一项为期24周的西酞普兰预防复发疗效研究中接受安慰剂治疗。与安慰剂相比，20毫克和40毫克西酞普兰组在复发方面（p<0.05）以及复发时间的生存分析方面（分别为p=0.01和p=0.02）均显示出显著优势。20毫克和40毫克西酞普兰的安全性和耐受性似乎相似，与安慰剂相比副作用差异不大。结果表明，20毫克和40毫克剂量的西酞普兰在巩固疗效的延续治疗中均有效且耐受性良好。在为期6周的急性治疗研究中对安慰剂有反应的患者，继续双盲服用安慰剂但未纳入疗效分析，其复发率与正式安慰剂对照组相似，这表明在短疗程治疗中对安慰剂有反应的患者可能仍需要长期积极治疗以预防复发。
